Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.880
+0.130 (7.43%)
At close: Apr 2, 2026
Company Description
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US, Inc.
| Country | United Arab Emirates |
| Founded | 2020 |
| IPO Date | May 9, 2025 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Vinod Menon |
Contact Details
Address: B4-204A5, Business Centre 04, RAKEZ Business Zone-FZ Ras al-Khaimah United Arab Emirates | |
| Website | mindwavedao.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1894525 |
| CUSIP Number | 03771D102 |
| ISIN Number | US03771D1028 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2026 | 425 | Filing |
| Apr 9, 2026 | 8-K/A | [Amend] Current report |
| Mar 31, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 30, 2026 | SCHEDULE 13D/A | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 20, 2026 | SCHEDULE 13D/A | Filing |
| Mar 16, 2026 | 8-K | Current Report |
| Feb 27, 2026 | DEFM14C | Filing |
| Feb 17, 2026 | 425 | Filing |